Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgements
This article was originally published in The Tan Sheet
Executive Summary
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
You may also be interested in...
FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29
FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29
FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29